trifluoperazine has been researched along with Lung Neoplasms in 15 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, brain metastases remain the biggest threat to the survival and quality of life of melanoma patients." | 5.62 | Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux. ( Lin, W; Xi, H; Xia, Y; Xie, Y; Xiong, M; Xu, F; Xue, Q; Yang, H; Ye, T; Yu, L, 2021) |
| "Trifluoperazine (TFP), which is an antipsychotic drug, has the ability to bind to NUPR1 and mimic NUPR1 deficiency in cancer cells." | 5.56 | Combination of AAV‑mediated NUPR1 knockdown and trifluoperazine induces premature senescence in human lung adenocarcinoma A549 cells in nude mice. ( Cui, B; Li, Y; Liu, Z; Ma, J; Ma, Z; Sun, Y; Yan, X; Yang, J; Yin, Y; Zhang, Y; Zhou, R, 2020) |
| " Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma." | 3.78 | Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. ( Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D, 2012) |
| " A significant potentiation of the P-30 protein-induced cell growth inhibition by tamoxifen as well as trifluoroperazine (Stelazine) in both the human A-549 lung carcinoma and the ASPC-1 pancreatic adenocarcinoma systems at wide ranges of drug concentrations was observed." | 3.68 | Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. ( Ardelt, W; Menduke, H; Mikulski, SM; Shogen, K; Viera, A, 1990) |
| "However, brain metastases remain the biggest threat to the survival and quality of life of melanoma patients." | 1.62 | Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux. ( Lin, W; Xi, H; Xia, Y; Xie, Y; Xiong, M; Xu, F; Xue, Q; Yang, H; Ye, T; Yu, L, 2021) |
| "Trifluoperazine (TFP), which is an antipsychotic drug, has the ability to bind to NUPR1 and mimic NUPR1 deficiency in cancer cells." | 1.56 | Combination of AAV‑mediated NUPR1 knockdown and trifluoperazine induces premature senescence in human lung adenocarcinoma A549 cells in nude mice. ( Cui, B; Li, Y; Liu, Z; Ma, J; Ma, Z; Sun, Y; Yan, X; Yang, J; Yin, Y; Zhang, Y; Zhou, R, 2020) |
| " The effects of ospemifene (OSP) on the immune response to a peptide cancer vaccine (PV) were evaluated after chronic [control (n = 22); OSP 50 mg/kg (n = 16); PV (n = 6); OSP+PV (n = 11)], intermittent [control (n = 10); OSP 10 and 50 mg/kg (n = 11); PV (n = 11); combination treatment (n = 11 each dose)] and pretreatment [control; OSP 100 mg/kg; PV 100 μg; combination treatment (n = 8 all groups)] ospemifene oral dosing schedules in a total of 317 mixed-sex tumor-bearing and nontumor-bearing mice." | 1.46 | Repurposing ospemifene for potentiating an antigen-specific immune response. ( DeGregorio, MW; Kao, CJ; Lin, YC; Phong, B; Vang, DP; Wurz, GT, 2017) |
| "Trifluoperazine (TFP) could inhibit the proliferation of A549 lung cancer cells and human embryo lung (HEL) cells." | 1.28 | [Action of calmodulin antagonist on the proliferation and cytoskeleton of A549 lung cancer cells]. ( Fan, X, 1992) |
| "Nifedipine was included as the standard or reference compound." | 1.28 | In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II). ( Honn, KV; Nelson, KK; Onoda, JM; Taylor, JD, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Yin, Y | 1 |
| Ma, J | 1 |
| Sun, Y | 1 |
| Zhou, R | 1 |
| Cui, B | 1 |
| Zhang, Y | 1 |
| Yang, J | 1 |
| Yan, X | 1 |
| Liu, Z | 1 |
| Ma, Z | 1 |
| Xia, Y | 1 |
| Xu, F | 1 |
| Xiong, M | 1 |
| Yang, H | 1 |
| Lin, W | 1 |
| Xie, Y | 1 |
| Xi, H | 1 |
| Xue, Q | 1 |
| Ye, T | 1 |
| Yu, L | 1 |
| Linxweiler, M | 1 |
| Schorr, S | 1 |
| Schäuble, N | 1 |
| Jung, M | 1 |
| Linxweiler, J | 1 |
| Langer, F | 1 |
| Schäfers, HJ | 1 |
| Cavalié, A | 1 |
| Zimmermann, R | 1 |
| Greiner, M | 1 |
| Kao, CJ | 1 |
| Wurz, GT | 1 |
| Lin, YC | 1 |
| Vang, DP | 1 |
| Phong, B | 1 |
| DeGregorio, MW | 1 |
| Sangodkar, J | 1 |
| Dhawan, NS | 1 |
| Melville, H | 1 |
| Singh, VJ | 1 |
| Yuan, E | 1 |
| Rana, H | 1 |
| Izadmehr, S | 1 |
| Farrington, C | 1 |
| Mazhar, S | 1 |
| Katz, S | 1 |
| Albano, T | 1 |
| Arnovitz, P | 1 |
| Okrent, R | 1 |
| Ohlmeyer, M | 1 |
| Galsky, M | 1 |
| Burstein, D | 1 |
| Zhang, D | 1 |
| Politi, K | 1 |
| Difeo, A | 1 |
| Narla, G | 1 |
| Yeh, CT | 1 |
| Wu, AT | 1 |
| Chang, PM | 1 |
| Chen, KY | 1 |
| Yang, CN | 1 |
| Yang, SC | 1 |
| Ho, CC | 1 |
| Chen, CC | 1 |
| Kuo, YL | 1 |
| Lee, PY | 1 |
| Liu, YW | 1 |
| Yen, CC | 1 |
| Hsiao, M | 1 |
| Lu, PJ | 1 |
| Lai, JM | 1 |
| Wang, LS | 1 |
| Wu, CH | 1 |
| Chiou, JF | 1 |
| Yang, PC | 1 |
| Huang, CY | 1 |
| Polischouk, AG | 1 |
| Holgersson, A | 1 |
| Zong, D | 1 |
| Stenerlöw, B | 1 |
| Karlsson, HL | 1 |
| Möller, L | 1 |
| Viktorsson, K | 1 |
| Lewensohn, R | 2 |
| Xiong, W | 1 |
| Shen, H | 1 |
| Eriksson, A | 1 |
| Yachnin, J | 1 |
| Nilsson, A | 1 |
| Nilsso, A | 1 |
| Fan, X | 1 |
| Zacharski, LR | 1 |
| Moritz, TE | 1 |
| Haakenson, CM | 1 |
| O'Donnell, JF | 1 |
| Ballard, HS | 1 |
| Johnson, GJ | 1 |
| Ringenberg, QS | 1 |
| Schilsky, RL | 1 |
| Spaulding, MB | 1 |
| Tornyos, K | 1 |
| Mikulski, SM | 1 |
| Viera, A | 1 |
| Ardelt, W | 1 |
| Menduke, H | 1 |
| Shogen, K | 1 |
| Onoda, JM | 1 |
| Nelson, KK | 1 |
| Taylor, JD | 1 |
| Honn, KV | 1 |
| Kennedy, MJ | 1 |
| Shelley, RK | 1 |
| Daly, PA | 1 |
| Ganapathi, R | 1 |
| Schmidt, H | 1 |
| Grabowski, D | 1 |
| Melia, M | 1 |
| Ratliff, N | 1 |
15 other studies available for trifluoperazine and Lung Neoplasms
| Article | Year |
|---|---|
Combination of AAV‑mediated NUPR1 knockdown and trifluoperazine induces premature senescence in human lung adenocarcinoma A549 cells in nude mice.
Topics: A549 Cells; Adenocarcinoma of Lung; Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Surv | 2020 |
Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux.
Topics: Animals; Antineoplastic Agents; Antipsychotic Agents; Autophagy; Bone Neoplasms; Brain Neoplasms; Ce | 2021 |
Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells.
Topics: Amino Acid Motifs; Amino Acid Sequence; Biomarkers, Tumor; Calcium; Calcium Signaling; Calmodulin; C | 2013 |
Repurposing ospemifene for potentiating an antigen-specific immune response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calmodulin; Cancer Vaccin | 2017 |
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agen | 2012 |
Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.
Topics: Animals; Antipsychotic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diseas | 2012 |
The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death.
Topics: Antipsychotic Agents; Bleomycin; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; DNA B | 2007 |
[Effect of calmodulin antagonist on chemosensitivity of primary cultured lung cancer cells].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Calmodu | 1995 |
DNA-dependent protein kinase is inhibited by trifluoperazine.
Topics: Blotting, Western; Cell Extracts; DNA-Activated Protein Kinase; DNA-Binding Proteins; Enzyme Inhibit | 2001 |
[Action of calmodulin antagonist on the proliferation and cytoskeleton of A549 lung cancer cells].
Topics: Calmodulin; Cell Division; Cells, Cultured; Cytoskeleton; Embryo, Mammalian; Humans; Lung; Lung Neop | 1992 |
Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study.
Topics: Calcium; Carcinoma, Small Cell; Cohort Studies; Colonic Neoplasms; Diltiazem; Humans; Lung Neoplasms | 1990 |
Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Division; Drug Synergism; Humans; Lung Neoplasms; Pancre | 1990 |
In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).
Topics: Animals; Calcium Channel Blockers; Cisplatin; Diltiazem; Drug Evaluation, Preclinical; Drug Resistan | 1989 |
Potentiation of small cell lung cancer-related SIADH by trifluoperazine.
Topics: Carcinoma, Small Cell; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lung Neoplasms; Male; Middl | 1987 |
Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
Topics: Animals; Cell Survival; Doxorubicin; Drug Interactions; Drug Resistance; In Vitro Techniques; Lung N | 1988 |